Corporate
Merck Beats Q4 Estimates But Guides Low as Gardasil Headwinds Persist
3d ago
You're signed outSign in or to get full access.
M&
Merck & Co. (MRK)·Earnings Reports
Q4 2025
View earnings summary and analysis
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering Merck & Co..
Recent News about Merck & Co.
Deals & Capital Markets
Merck Walks Away From $30 Billion Revolution Medicines Deal; Stock Plunges 22%
Jan 26
Deals & Capital Markets
Merck Emerges as Lead Suitor for Revolution Medicines at $28-32 Billion
Jan 9
Corporate
Patient Deaths Halt Merck's $5.5 Billion ADC Trial: Second Major Blow to Daiichi Partnership
Dec 20, 2025